BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 32047993)

  • 1. Positron emission tomography (PET) radiotracers for prostate cancer imaging.
    Walker SM; Lim I; Lindenberg L; Mena E; Choyke PL; Turkbey B
    Abdom Radiol (NY); 2020 Jul; 45(7):2165-2175. PubMed ID: 32047993
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Clinical Indications for (18)F/(11)C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature.
    Evangelista L; Briganti A; Fanti S; Joniau S; Reske S; Schiavina R; Stief C; Thalmann GN; Picchio M
    Eur Urol; 2016 Jul; 70(1):161-175. PubMed ID: 26850970
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    von Eyben FE; Picchio M; von Eyben R; Rhee H; Bauman G
    Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Imaging in Detection of Metastatic Prostate Cancer.
    Smith CP; Laucis A; Harmon S; Mena E; Lindenberg L; Choyke PL; Turkbey B
    Curr Oncol Rep; 2019 Mar; 21(4):31. PubMed ID: 30834999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Systematic Review on the Role of Imaging in Early Recurrent Prostate Cancer.
    De Visschere PJL; Standaert C; Fütterer JJ; Villeirs GM; Panebianco V; Walz J; Maurer T; Hadaschik BA; Lecouvet FE; Giannarini G; Fanti S
    Eur Urol Oncol; 2019 Feb; 2(1):47-76. PubMed ID: 30929846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of PET/CT in prostate cancer.
    Li R; Ravizzini GC; Gorin MA; Maurer T; Eiber M; Cooperberg MR; Alemozzaffar M; Tollefson MK; Delacroix SE; Chapin BF
    Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):4-21. PubMed ID: 29230009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review of commonly used prostate specific PET tracers used in prostate cancer imaging in current clinical practice.
    Niaz MJ; Sun M; Skafida M; Niaz MO; Ivanidze J; Osborne JR; O'Dwyer E
    Clin Imaging; 2021 Nov; 79():278-288. PubMed ID: 34182326
    [No Abstract]   [Full Text] [Related]  

  • 9. PET Imaging for Prostate Cancer.
    Savir-Baruch B; Werner RA; Rowe SP; Schuster DM
    Radiol Clin North Am; 2021 Sep; 59(5):801-811. PubMed ID: 34392920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Targets for PET Molecular Imaging of Prostate Cancer.
    Mena E; Lindenberg LM; Choyke PL
    Semin Nucl Med; 2019 Jul; 49(4):326-336. PubMed ID: 31227055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recurrent prostate cancer detection with anti-3-[(18)F]FACBC PET/CT: comparison with CT.
    Odewole OA; Tade FI; Nieh PT; Savir-Baruch B; Jani AB; Master VA; Rossi PJ; Halkar RK; Osunkoya AO; Akin-Akintayo O; Zhang C; Chen Z; Goodman MM; Schuster DM
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1773-83. PubMed ID: 27091135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Prostate Cancer with Radiolabeled Amino Acid Analogs.
    Schuster DM; Nanni C; Fanti S
    J Nucl Med; 2016 Oct; 57(Suppl 3):61S-66S. PubMed ID: 27694174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison Between
    Cantiello F; Crocerossa F; Russo GI; Gangemi V; Ferro M; Vartolomei MD; Lucarelli G; Mirabelli M; Scafuro C; Ucciero G; De Cobelli O; Morgia G; Damiano R; Cascini GL
    Clin Genitourin Cancer; 2018 Oct; 16(5):385-391. PubMed ID: 29937067
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Five-year trends of bone scan and prostate-specific membrane antigen positron emission tomography utilization in prostate cancer: A retrospective review in a private centre.
    Haran C; McBean R; Parsons R; Wong D
    J Med Imaging Radiat Oncol; 2019 Aug; 63(4):495-499. PubMed ID: 30972933
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapidly changing landscape of PET/CT imaging in prostate cancer.
    Morigi JJ; Fanti S; Murphy D; Hofman MS
    Curr Opin Urol; 2016 Sep; 26(5):493-500. PubMed ID: 27467137
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prostate Cancer: Prostate-specific Membrane Antigen Positron-emission Tomography/Computed Tomography or Positron-emission Tomography/Magnetic Resonance Imaging for Staging.
    Ferraro DA; Burger IA
    Top Magn Reson Imaging; 2020 Feb; 29(1):59-66. PubMed ID: 32015295
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Malaspina S; De Giorgi U; Kemppainen J; Del Sole A; Paganelli G
    Radiol Med; 2018 Dec; 123(12):952-965. PubMed ID: 30116970
    [TBL] [Abstract][Full Text] [Related]  

  • 18. (18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET/CT in prostate cancer relapse: results of a prospective trial.
    Nanni C; Zanoni L; Pultrone C; Schiavina R; Brunocilla E; Lodi F; Malizia C; Ferrari M; Rigatti P; Fonti C; Martorana G; Fanti S
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1601-10. PubMed ID: 26960562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Positron emission tomography with computed tomography/magnetic resonance imaging for primary staging of prostate cancer].
    Hasa E; Langbein T; Eiber M; Knorr K
    Radiologe; 2021 Sep; 61(9):818-824. PubMed ID: 34351430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 18F-Fluciclovine PET/CT for the Detection of Prostate Cancer Relapse: A Comparison to 11C-Choline PET/CT.
    Nanni C; Schiavina R; Brunocilla E; Boschi S; Borghesi M; Zanoni L; Pettinato C; Martorana G; Fanti S
    Clin Nucl Med; 2015 Aug; 40(8):e386-91. PubMed ID: 26053708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.